GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: example 1 [WO2016094821A2]
                                 
                                                         
                            
                            
                            
                                 
                                
                                rezivertinib is an approved drug 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: The chemical structure submitted to the WHO for INN rezivertinib, is identical to the structure of example 1 that is claimed in patent WO2016094821A2 by Beta Pharma [1]. This patent claims novel EGFR inhibitors that are active against mutated EGFRs that are found in cancers, i.e. third generation EGFR inhibitors. From Beta Pharma's declared pipeline, example 1 is likely to be BPI-7711, which is being investigated for the treatment of EGFRT790M-mutant non-small cell lung cancer. We await formal name>structure confirmation. Experimental evidence in WO2016094821A2 indicates that example 1 is orally bioavailable.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
Classification ![]()  | 
                                                    |
| Compound class | Synthetic organic | 
| Approved drug? | Yes. China NMPA (2024) | 
International Nonproprietary Names ![]()  | 
                                                        |
| INN number | INN | 
| 11229 | rezivertinib | 
Synonyms ![]()  | 
                                                        
| example 1 [WO2016094821A2] | 
Database Links ![]()  | 
                                                        |
| GtoPdb PubChem SID | 404859075 | 
| PubChem CID | 118912975 | 
| Search Google for chemical match using the InChIKey | BPMZUKYFIDPLEA-UHFFFAOYSA-N | 
| Search Google for chemicals with the same backbone | BPMZUKYFIDPLEA | 
| Search PubMed clinical trials | rezivertinib | 
| Search PubMed titles | rezivertinib | 
| Search PubMed titles/abstracts | rezivertinib | 
| UniChem Compound Search for chemical match using the InChIKey | BPMZUKYFIDPLEA-UHFFFAOYSA-N | 
| UniChem Connectivity Search for chemical match using the InChIKey | BPMZUKYFIDPLEA-UHFFFAOYSA-N | 
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖| 
                                                                     
                                                                         
                                                                         
                                                                             
                                                                         
                                                                         
                                                                           
                                                                           Rezivertinib (links to external site) 
                                                                    
                                                                Cat. No. HY-109189  |